Holen Sie sich die Stockscreener-App
9.60
3.34%
-0.39
Schlusskurs vom Vortag:
$9.99
Offen:
$10
24-Stunden-Volumen:
633.30K
Relative Volume:
0.84
Marktkapitalisierung:
$396.36M
Einnahmen:
$128.29M
Nettoeinkommen (Verlust:
$-30.69M
KGV:
-11.71
EPS:
-0.82
Netto-Cashflow:
$-27.17M
1W Leistung:
-7.33%
1M Leistung:
-23.55%
6M Leistung:
-22.32%
1J Leistung:
-72.88%
1-Tages-Spanne:
$9.58
$10.00
1-Wochen-Bereich:
$9.58
$10.85
52-Wochen-Spanne:
$6.32
$35.60
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Vergleichen Sie RXST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
9.64 | 410.76M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
127.09 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.88 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.81 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.86 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
Will RxSight Inc. stock outperform international peers2026 world cup usa national team group stage playmakers possession football tactical prediction tactical review - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ... - Bluefield Daily Telegraph
Looking At The Narrative For RxSight (RXST) After A Better Than Feared Quarter - Yahoo Finance
RxSight CFO Shelley Thunen to Step Down - Orange County Business Journal
Income Plays: Will RxSight Inc stock outperform value stocksEarnings Growth Summary & Low Risk High Win Rate Picks - moha.gov.vn
RxSight director sells $108,618 in common stock - MSN
Trading the Move, Not the Narrative: (RXST) Edition - Stock Traders Daily
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference - The Manila Times
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - PR Newswire
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Shareholders to Reach Out - ACCESS Newswire
Institutional Owners May Take Dramatic Actions as RxSight, Inc.'s (NASDAQ:RXST) Recent 13% Drop Adds to One-year Losses - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
RxSight enters transition agreement with outgoing CFO Shelley Thunen By Investing.com - Investing.com Australia
RxSight, Inc. Announces Transition of Chief Financial Officer Shelley Thunen - VisionMonday.com
RxSight enters transition agreement with outgoing CFO Shelley Thunen - Investing.com
RxSight Announces CFO Transition and Leadership Continuity Plan - TipRanks
RxSight Announces CFO Transition - TradingView — Track All Markets
RxSight (RXST) sets CFO transition and consulting deal, keeps 2025 outlook - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
RxSight CFO exit raises concerns over pace of recovery, BTIG says - Investing.com Canada
RxSight (NASDAQ:RXST) Shares Gap DownShould You Sell? - MarketBeat
RxSight Shares Fall After Company Says CFO Shelley Thunen to Step Down - marketscreener.com
RxSight down on CFO transition (RXST:NASDAQ) - Seeking Alpha
RxSight Chief Financial Officer Shelley Thunen to Step Down - marketscreener.com
Rxsight, Inc. announces chief financial officer transition - marketscreener.com
RxSight announces planned transition of longtime CFO Thunen - TipRanks
RXST FinancialsIncome Statement - Quiver Quantitative
RxSight, Inc. Announces CFO Transition - TradingView — Track All Markets
RxSight, Inc. Announces Chief Financial Officer Transition - GlobeNewswire
Tunwal E Rebound Backed by Sentiment ShiftPrice Support Zones & Free Real-Time Trading Alerts Every Day - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Thrivent Financial for Lutherans Lowers Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight Announces Executive Leadership Reorganization and New Appointments - TipRanks
RxSight, Inc. Announces Executive Appointments - TradingView — Track All Markets
RxSight, Inc. Appoints Eric Weinberg as Chief Business Development Officer and Scott Gaines as Chief Customer Officer, Effective December 18, 2025 - marketscreener.com
RxSight Earnings Notes - Trefis
Why RxSight Inc. stock is a value investor pickDip Buying & Safe Entry Trade Signal Reports - DonanımHaber
Will RxSight Inc. stock outperform value stocks2025 Sector Review & Expert Verified Stock Movement Alerts - DonanımHaber
Is RxSight Inc. stock trading at a premium valuationJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
RxSight announces executive leadership reorganization and new appointments - MSN
Midday Stock Roundup: RXSight Falls After CFO Announcement - Orange County Business Journal
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Squarepoint Ops LLC Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
How the Narrative Surrounding RxSight Is Shifting After a Strong but Debated Quarter - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Wells Fargo Reaffirms Their Hold Rating on RxSight (RXST) - The Globe and Mail
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):